Difference between revisions of "Interferon alfa-2b (Intron-A)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "[[Category:Adult T-cell leukemia/lymphoma" to "[[Category:Adult T-cell leukemia-lymphoma")
m
Line 10: Line 10:
 
*[[Chronic myelogenous leukemia]]
 
*[[Chronic myelogenous leukemia]]
 
*[[Hairy cell leukemia]]
 
*[[Hairy cell leukemia]]
 +
*[[Kaposi sarcoma]]
 
*[[Melanoma]]
 
*[[Melanoma]]
 
*[[Multiple myeloma]]
 
*[[Multiple myeloma]]
Line 29: Line 30:
 
* Indicated as adjuvant to surgical treatment in patients 18 years of age or older with [[Melanoma|malignant melanoma]] who are free of disease but at high risk for systemic recurrence, within 56 days of surgery.
 
* Indicated as adjuvant to surgical treatment in patients 18 years of age or older with [[Melanoma|malignant melanoma]] who are free of disease but at high risk for systemic recurrence, within 56 days of surgery.
 
* Indicated for the initial treatment of clinically aggressive [[Follicular_lymphoma|follicular Non-Hodgkin’s Lymphoma]] in conjunction with anthracycline-containing combination chemotherapy in patients 18 years of age or older. Efficacy of INTRON A therapy in patients with low-grade, low tumor burden follicular Non-Hodgkin’s Lymphoma has not been demonstrated.
 
* Indicated for the initial treatment of clinically aggressive [[Follicular_lymphoma|follicular Non-Hodgkin’s Lymphoma]] in conjunction with anthracycline-containing combination chemotherapy in patients 18 years of age or older. Efficacy of INTRON A therapy in patients with low-grade, low tumor burden follicular Non-Hodgkin’s Lymphoma has not been demonstrated.
−
* Indicated for the treatment of selected patients 18 years of age or older with [[Vascular_sarcoma|AIDS-Related Kaposi's Sarcoma]].
+
* Indicated for the treatment of selected patients 18 years of age or older with [[Kaposi sarcoma|AIDS-Related Kaposi's Sarcoma]].
  
 
==Also known as==
 
==Also known as==
Line 68: Line 69:
 
|-
 
|-
 
|Interferonum Leucocyticum
 
|Interferonum Leucocyticum
 +
|Intron-A
 
|Laroferon
 
|Laroferon
 
|Multiferon
 
|Multiferon
 
|Namalvin
 
|Namalvin
 +
|-
 
|OIF
 
|OIF
−
|-
 
 
|Polyferon
 
|Polyferon
 
|Realdiron
 
|Realdiron
 
|Roceron-A
 
|Roceron-A
 
|Sumiferon
 
|Sumiferon
 +
|-
 
|Wellferon
 
|Wellferon
 
|-
 
|-
Line 96: Line 99:
 
[[Category:Chronic myelogenous leukemia medications]]
 
[[Category:Chronic myelogenous leukemia medications]]
 
[[Category:Hairy cell leukemia medications]]
 
[[Category:Hairy cell leukemia medications]]
 +
[[Category:Kaposi sarcoma medications]]
 
[[Category:Melanoma medications]]  
 
[[Category:Melanoma medications]]  
 
[[Category:Multiple myeloma medications]]
 
[[Category:Multiple myeloma medications]]

Revision as of 15:29, 23 January 2020

General information

Class/mechanism: Immune system activator; binds to cell surface receptors that modulate many downstream intracellular signal transduction pathways. Mechanism not fully understood.[1][2][3]
Route: SC, IM, IV, intralesional
Extravasation: no information

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Diseases for which it was used

Patient drug information

History of changes in FDA indication

  • 6/4/1986: Initial FDA approval
  • Indicated for the treatment of patients 18 years of age or older with hairy cell leukemia.
  • Indicated as adjuvant to surgical treatment in patients 18 years of age or older with malignant melanoma who are free of disease but at high risk for systemic recurrence, within 56 days of surgery.
  • Indicated for the initial treatment of clinically aggressive follicular Non-Hodgkin’s Lymphoma in conjunction with anthracycline-containing combination chemotherapy in patients 18 years of age or older. Efficacy of INTRON A therapy in patients with low-grade, low tumor burden follicular Non-Hodgkin’s Lymphoma has not been demonstrated.
  • Indicated for the treatment of selected patients 18 years of age or older with AIDS-Related Kaposi's Sarcoma.

Also known as

Caution, may also contain names for interferon beta, interferon gamma, or interferon alfa-2a.

  • Brand names:
Synonyms
Advaferon Alfaferone Berofor Biogamma Canferon A
Cytoferon Egiferon Feron Fiblaferon Frone
Finnferon-Alpha Heberon Alfa R Humoferon IFN Alpha Imufor
Imukin INF Inferax Infergen Inmutag
Interfero Interferon Alfanative Interferon Human Interferon Leucocyticum Interferon Lymphoblastoid
Interferonum Leucocyticum Intron-A Laroferon Multiferon Namalvin
OIF Polyferon Realdiron Roceron-A Sumiferon
Wellferon

References

  1. ↑ 1.0 1.1 Interferon alfa-2b (Intron-A) package insert
  2. ↑ Interferon alfa-2b (Intron-A) package insert (locally hosted backup)
  3. ↑ Intron-A manufacturer's website
  4. ↑ Interferon alfa-2b (Intron-A) patient drug information (Chemocare)
  5. ↑ Interferon alfa-2b (Intron-A) patient drug information (UpToDate)
Retrieved from "https://hemonc.org/w/index.php?title=Interferon_alfa-2b_(Intron-A)&oldid=42269"